Treatment of secondary movement disorders related to midbrain cavernomas
Objective: To evaluate possible efficacy and safety of standard antiparkinsonian drugs (levodopa formulations, amantadine) in patients with symptomatic midbrain cavernomas (haemorhage and/or surgery) and secondary…Levodopa effect and motor function in late stage Parkinson’s disease
Objective: To assess responsiveness to Levodopa (L-dopa) in patients with late stage Parkinson’s disease (PD). Moreover, to investigate if the L-dopa effect is stable or…Association between clinical features and pre- and post-synaptic dopaminergic dysfunction in multiple system atrophy: [18F]-FP-CIT PET and [18F]-FDG PET analyses
Objective: To investigate the correlation between clinical features and pre- and post-synaptic dopaminergic dysfunction in patients with multiple system atrophy (MSA). Background: Multiple system atrophy…Influence of levodopa on functional brain connectivity in Parkinson’s disease
Objective: To evaluate how functional connectivity estimated by resting-state functional magnetic resonance imaging (rs-fMRI) is influenced by levodopa and associated with clinical symptoms in Parkinson's…Impact of chronic LD treatment on metabolism, blood flow and blood-brain barrier permeability in the 6-OHDA rat model
Objective: To determine the effects of chronic LD treatment and induction of dyskinesias on cerebral metabolism, blood flow and blood-brain barrier permeability in 6-OHDA rat…Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease
Objective: To demonstrate feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist and nurse satisfaction. Background: LCIG, is used for…Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study
Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations
Objective: Two Phase 2 studies were conducted to evaluate the safety profile of inhaled CVT-301 administered to Parkinson's disease (PD) patients with motor fluctuations. Background:…Impact of comorbidities and compliance initiatives in management of patients with early Parkinson’s disease
Objective: To evaluate the impact of comorbidities and compliance iniciatives on treatment efficacy in patients with Parkinson's disease. Methods: In the year 2014 we included…The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease
Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 57
- Next Page »